Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Articles published by Ambry Genetics
Ambry Genetics’ CARE Program Validated for Accuracy in Identifying High-Risk Patients for Hereditary Cancer Testing
June 25, 2025
From
Ambry Genetics
Via
Business Wire
Tickers
TEM
Ambry Genetics Data Supports Functional Study of BRCA2, Helping Improve Variant Classification for Hereditary BRCA2-Linked Cancers
January 08, 2025
From
Ambry Genetics
Via
Business Wire
New Study Shows Impact of Ambry Genetics’ Patient for Life™ Program on Rare Disease Diagnosis
May 27, 2025
From
Ambry Genetics
Via
Business Wire
Tickers
TEM
Ambry Genetics Announces New Hereditary Cancer Test Menu at NSGC Annual Conference
September 17, 2024
From
Ambry Genetics
Via
Business Wire
Ambry Genetics Announces New Multiomic Exome Test for Improved Rare Disease Detection
August 19, 2024
From
Ambry Genetics
Via
Business Wire
Ambry Genetics Announces a Collaboration with Tempus to Advance Paired Germline and Somatic Testing Services for Medical Oncologists
March 12, 2024
From
Ambry Genetics
Via
Business Wire
Ambry Genetics Unveils at ASHG New Insights on the Use of Multiomic Testing in 43,000 Patient Study
November 04, 2023
From
Ambry Genetics
Via
Business Wire
LifeStrands Genomics and Ambry Genetics to Provide Laboratory Testing for Clinical Implementation Pilots in Phase II of Singapore’s National Precision Medicine Programme
April 19, 2023
From
Ambry Genetics
Via
Business Wire
Unilabs and Ambry Sign Agreement to Enhance Genetic Testing Services for Biopharma Companies in Europe, Latin America and the Middle East
January 26, 2023
From
Ambry Genetics
Via
Business Wire
Ambry’s New Reproductive Health Program Uses Digital Platform to Make It Easier for Patients to Access Genetic Screening Before and During Pregnancy
October 19, 2022
From
Ambry Genetics
Via
Business Wire
Ambry Genetics Publishes 43,000 Patient Study Showing Combined RNA and DNA Analysis Identifies Patients Who Are High-Risk for Cancer but Would Have Been Missed by DNA Testing Alone
August 29, 2022
From
Ambry Genetics
Via
Business Wire
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.